MAXIMISE Trial - Secukinumab Efficacy in Psoriatic Spondylitis Patients Save
The results of the novel MAXIMISE trial have been published, demonstrating that secukinumab (SEC) significantly improved axial signs and symptoms in psoriatic arthritis (PsA) patients with axial manifestations with inadequate NSAID response.
The MAXIMISE (Managing AXIal Manifestations in psorIatic arthritis with SEcukinumab) study to done to see if SEC would be equally effective in treating axial disesase in PsA as it is in treating axial disease in ankylosing spondylitis and spondyloarthritis.
The trial was a double-blind, placebo-controlled, 52-week study that enrolled 332 patients with PsA with spinal pain (BASDAI ≥4) despite use of at least two prior NSAIDs). The primary endpoint was ASAS20 (Assessment of SpondyloArthritis international Society) response at week 12.
At week 12, secukinumab 300 mg and 150 mg treated patients were significantly improved compared to placebo (63% and 66% vs 31% placebo).
No new safety signals were found in this trial.
Hence, for the 10-20% of PsA patients who have axial symptoms or over Psoriatic spondylitis, SEC appears to be an effective treatment option.